Cytosorbents (CTSO) Competitors $1.00 -0.01 (-0.99%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CTSO vs. ARAY, SMLR, ELMD, NVRO, NPCE, PROF, LUCY, BWAY, GUTS, and DRTSShould you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include Accuray (ARAY), Semler Scientific (SMLR), Electromed (ELMD), Nevro (NVRO), NeuroPace (NPCE), Profound Medical (PROF), Innovative Eyewear (LUCY), BrainsWay (BWAY), Fractyl Health (GUTS), and Alpha Tau Medical (DRTS). These companies are all part of the "medical" sector. Cytosorbents vs. Accuray Semler Scientific Electromed Nevro NeuroPace Profound Medical Innovative Eyewear BrainsWay Fractyl Health Alpha Tau Medical Cytosorbents (NASDAQ:CTSO) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking. Do analysts rate CTSO or ARAY? Cytosorbents presently has a consensus target price of $2.00, indicating a potential upside of 100.00%. Accuray has a consensus target price of $9.00, indicating a potential upside of 414.29%. Given Accuray's higher possible upside, analysts clearly believe Accuray is more favorable than Cytosorbents.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Accuray 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, CTSO or ARAY? Cytosorbents has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Which has stronger valuation & earnings, CTSO or ARAY? Accuray has higher revenue and earnings than Cytosorbents. Accuray is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytosorbents$36.35M1.50-$28.51M-$0.53-1.89Accuray$446.55M0.39-$15.55M-$0.16-10.94 Does the MarketBeat Community prefer CTSO or ARAY? Cytosorbents received 106 more outperform votes than Accuray when rated by MarketBeat users. Likewise, 76.27% of users gave Cytosorbents an outperform vote while only 65.67% of users gave Accuray an outperform vote. CompanyUnderperformOutperformCytosorbentsOutperform Votes43776.27% Underperform Votes13623.73% AccurayOutperform Votes33165.67% Underperform Votes17334.33% Do institutionals and insiders hold more shares of CTSO or ARAY? 32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by company insiders. Comparatively, 4.2% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to CTSO or ARAY? In the previous week, Cytosorbents had 1 more articles in the media than Accuray. MarketBeat recorded 3 mentions for Cytosorbents and 2 mentions for Accuray. Cytosorbents' average media sentiment score of 0.39 beat Accuray's score of 0.37 indicating that Cytosorbents is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Accuray 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CTSO or ARAY more profitable? Accuray has a net margin of -3.48% compared to Cytosorbents' net margin of -68.70%. Accuray's return on equity of -33.65% beat Cytosorbents' return on equity.Company Net Margins Return on Equity Return on Assets Cytosorbents-68.70% -131.84% -50.72% Accuray -3.48%-33.65%-3.30% SummaryAccuray beats Cytosorbents on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyTrue paradigm shiftI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Cytosorbents News Delivered to You Automatically Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTSO vs. The Competition Export to ExcelMetricCytosorbentsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.43M$4.41B$5.54B$8.53BDividend YieldN/A42.37%5.13%4.14%P/E Ratio-1.8938.74114.8115.14Price / Sales1.5065.081,495.55100.10Price / CashN/A49.0939.6734.08Price / Book1.924.264.665.02Net Income-$28.51M$11.52M$119.06M$225.46M7 Day Performance-3.85%1.06%0.80%0.37%1 Month Performance-25.37%0.92%5.65%3.57%1 Year Performance-33.33%39.37%36.75%29.43% Cytosorbents Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTSOCytosorbents1.9 of 5 stars$1.00-1.0%$2.00+100.0%-32.0%$54.43M$36.35M-1.89186Upcoming EarningsAnalyst ForecastNews CoverageARAYAccuray4.2229 of 5 stars$1.86-0.5%$9.00+383.9%-31.9%$184.59M$446.55M-11.63987Upcoming EarningsSMLRSemler Scientific1.678 of 5 stars$30.82+4.2%N/A+7.2%$215.49M$61.74M15.1192Upcoming EarningsHigh Trading VolumeELMDElectromedN/A$22.87+2.2%N/A+118.9%$197.96M$54.72M39.43174NVRONevro2.5994 of 5 stars$5.25+6.9%$10.55+100.9%-62.0%$195.72M$425.17M-2.461,215Analyst UpgradeNPCENeuroPace3.3184 of 5 stars$6.49+1.7%$14.00+115.7%-8.8%$189.51M$65.42M-5.95170Gap UpPROFProfound Medical2.1805 of 5 stars$7.35-2.5%$13.75+87.1%-13.3%$185.95M$7.88M-6.02150Upcoming EarningsNews CoveragePositive NewsLUCYInnovative Eyewear3.1268 of 5 stars$7.71+28.9%$20.00+159.4%-14.9%$181M$1.53M-0.709Gap UpHigh Trading VolumeBWAYBrainsWay3.0354 of 5 stars$9.99-0.3%$13.17+31.8%+180.3%$166.61M$36.43M199.84120Gap UpGUTSFractyl Health1.6187 of 5 stars$3.40+23.2%$22.00+547.1%N/A$162.85M$119,000.000.00102Gap UpHigh Trading VolumeDRTSAlpha Tau Medical2.151 of 5 stars$2.33+5.4%$8.00+243.3%-32.7%$162.33MN/A-5.8380Gap UpHigh Trading Volume Related Companies and Tools Related Companies ARAY Competitors SMLR Competitors ELMD Competitors NVRO Competitors NPCE Competitors PROF Competitors LUCY Competitors BWAY Competitors GUTS Competitors DRTS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTSO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytosorbents With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
